Display options
Cite
Allegaert K, Cosaert K, van den Anker JN. Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach. Curr Pharm Des. 2015;21(39):5674-9doi: 10.2174/1381612821666150901110207.
Allegaert, K., Cosaert, K., & van den Anker, J. N. (2015). Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach. Current pharmaceutical design, 21(39), 5674-9. https://doi.org/10.2174/1381612821666150901110207
Allegaert, Karel, et al. "Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach." Current pharmaceutical design vol. 21,39 (2015): 5674-9. doi: https://doi.org/10.2174/1381612821666150901110207
Allegaert K, Cosaert K, van den Anker JN. Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach. Curr Pharm Des. 2015;21(39):5674-9. doi: 10.2174/1381612821666150901110207. PMID: 26323412.
Copy Download .nbib Format: NLM
Share it on

Curr Pharm Des. 2015;21(39):5674-9. doi: 10.2174/1381612821666150901110207.

Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach.

Current pharmaceutical design

Karel Allegaert, Katrien Cosaert, John N van den Anker

Affiliations

  1. Neonatal Intensive Care Unit, University Hospital, Herestraat 49, 3000 Leuven, BELGIUM. [email protected].

PMID: 26323412 DOI: 10.2174/1381612821666150901110207

Abstract

To attain effective and safe pharmacotherapy in neonates, caregivers have to consider both the clinical characteristics of the newborn and the pharmacokinetic estimates of a given compound during prescription and administration. Overall, clearance in neonates is low when compared to other pediatric subpopulations. Despite this overall low clearance, there is already extensive between individual variability in clearance in early life. As a consequence, neonates are in urgent need of tailored drug product development that considers the need for both low and flexible dosing to maintain dose accuracy. During the development of such formulations tailored for neonates, there is also a need for guidance on excipient exposure. The available knowledge on the safety or toxicity of excipients is limited and difficult to retrieve, but there are initiatives (e.g. Safety and Toxicity of Excipients for Pediatrics [STEP] database initiative) to improve the present situation. In addition, population focussed studies on aspects of clinical pharmacology of excipients in neonates should be conducted. The propylene glycol research project and the European Study for Neonatal Excipient Exposure (ESNEE) initiative illustrate its feasibility. Finally, until tailored formulations make it to the market, compounding practices for drug formulations in neonates should be evaluated to guarantee correct dosing, product stability, safety and to support pharmacists in their daily practice.

MeSH terms

Publication Types

Grant support